Category Archives: General HIV+ population

BACKGROUND: More than half of people with HIV are now older than 50 years, and they face an approximately 60% higher risk of developing dementia compared with the general population....

BACKGROUND: Bacterial immunostimulants, such as lysates and trained-immunity vaccines, reduce recurrent respiratory infections and modulate immunity in immunodeficient patients. However, heterogeneity of preparations and limited safety data call for standardized...

Objective This systematic review aimed to assess the available literature on the subgingival bacterial microbiota profiles of PLHIV undergoing HAART. Materials and Methods This research was conducted in accordance with...

Objectives Poor hypertension prevention among people living with HIV (PLHIV) in sub-Saharan Africa may undermine progress in HIV prevention achieved within this population. This review synthesizes data on the prevalence,...

Introduction Despite administering combination antiretroviral therapy (cART), people living with the human immunodeficiency virus (PLWH) have been identified to be at an elevated risk of cardiovascular diseases (CVDs). Notably, inflammation...

OBJECTIVES: Tuberculosis and Human Immunodeficiency Virus (HIV) are two diseases that have imposed the heaviest burden globally. This study aims to determine the global prevalence of Mycobacterium tuberculosis and HIV...

Background Adherence to antiretroviral therapy (ART) is vital for controlling the viral load and disease progression in people living with HIV. Previous reviews on ART adherence among youths living with...

Background Metabolic syndrome (MetS) among people living with HIV (PLHIV) is an emerging concern in Africa, but its underlying causes remain unclear. This study is a systematic review and meta-analysis...

Introduction People living with HIV (PLHIV) are at an increased risk of type 2 diabetes mellitus (T2DM) due to aging, lifestyle, and antiretroviral therapy-related factors. This systematic review and meta-analysis...

COVID-19, caused by SARS-CoV-2, accounts for 186 million infections and more than 4 million deaths globally. This systematic review concentrates on the epidemiological profiling of HIV/AIDS, along with the unique...

BACKGROUND: Antiretroviral therapy is widely available, yet structural, social, and cultural barriers still limit human immunodeficiency virus prevention and care. Prevention tools such as consistent condom use and pre-exposure prophylaxis...

Background There is a global need for a rapid, accurate, and non-sputum point-of-care (PoC) assay for tuberculosis (TB), especially for people with HIV (PLHIV). The Fujifilm SILVAMP TB LAM (FujiLAM),...